The amount of t-cell engagers that are being developed is increasing more and more. Do they know something that we don't? š±
VIR-5500 is a novel dual-masked T-cell engager targeting prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC).
In an ongoing Phase 1 trial, all 12 participants experienced reductions in PSA levels, with 58% achieving a PSA50 response (ā„50% reduction).
The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities up to 1000 Āµg/kg and minimal low-grade cytokine release syndrome. These findings suggest that VIR-5500 may offer a promising therapeutic option for mCRPC patients.
SGLT-2 Inhibitors to (partially) āStarveā Glucose Dependent Cancers
Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy
Immune Discovery 'may treat all cancer' - A potential new breaktrough in CRISPR T-cell Immunotherapy - BBC - 20 January 2020